Therapeutic Apheresis Shows Promise as Alternative Treatment for Advanced Parkinson’s Disease
Therapeutic apheresis, a procedure that removes harmful substances from the blood, is being explored as a potential treatment for advanced Parkinson’s disease, according to a 2023 review published in *Neurotherapeutics*. The study highlights that the therapy may benefit patients who do not respond to conventional treatments, though more research is needed to confirm its efficacy.
What is Therapeutic Apheresis?
Therapeutic apheresis involves separating blood components and removing specific elements, such as immune cells or proteins, before returning the rest to the body. This approach is used in conditions like autoimmune disorders and certain cancers. In Parkinson’s disease, researchers hypothesize that the procedure could reduce neuroinflammation, a factor linked to disease progression.
“The theory is that by targeting inflammatory markers in the blood, apheresis might slow the degeneration of dopamine-producing neurons,” said Dr. Michael Schneck, a neurologist at the University of Michigan, in a 2023 interview with *Parkinson’s News Today*. “However, the evidence remains preliminary.”
Clinical Evidence and Recent Studies
A 2022 pilot study in *Movement Disorders* evaluated 15 patients with advanced Parkinson’s who underwent apheresis. The results showed modest improvements in motor function and quality of life, though the sample size was small. Larger trials are underway, including a Phase 2 trial sponsored by the National Institutes of Health (NIH), which is expected to enroll 100 participants.
“While these findings are encouraging, they must be interpreted cautiously,” noted Dr. Sarah Lin, a Parkinson’s researcher at the Mayo Clinic. “The lack of a control group in early studies limits conclusions about the therapy’s true impact.”
Comparing Treatment Options
Traditional Parkinson’s treatments include levodopa, dopamine agonists, and deep brain stimulation. Apheresis is considered an immunomodulatory approach, distinct from these methods. A 2023 analysis in *The Lancet Neurology* compared immunotherapies for neurodegenerative diseases, highlighting that apheresis remains an experimental option with limited long-term data.
“It’s not a replacement for existing therapies but a potential adjunct,” said Dr. Lin. “Patients should discuss risks and benefits with their care team before pursuing it.”
What’s Next for Research?
The NIH trial, set to conclude in 2025, will assess apheresis’s safety and efficacy in a larger cohort. Researchers also aim to identify biomarkers that could predict which patients might respond best to the treatment.
“If successful, this could open new avenues for personalized care,” said Dr. Schneck. “But we need robust evidence before it becomes standard practice.”
Why This Matters
Parkinson’s disease affects over 10 million people globally, with no cure currently available. Innovations like apheresis offer hope for patients who exhaust conventional options. However, experts caution against overestimating its potential without further validation.
“Patients and families must remain vigilant about unproven therapies,” emphasized Dr. Lin. “Rigorous science is the only path to reliable treatments.”